Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

9 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clonal competition with alternating dominance in multiple myeloma

ABSTRACT: This SuperSeries is composed of the following subset Series: GSE36822: Clonal competition with alternating dominance in multiple myeloma [244kCGH] GSE36823: Clonal competition with alternating dominance in multiple myeloma [44kCGH] GSE36824: Clonal competition with alternating dominance in multiple myeloma [GEP] Refer to individual Series

ORGANISM(S): Homo sapiens

SUBMITTER: Jonathan Keats

PROVIDER: E-GEOD-36825 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Project description:Clonal competition with alternating dominance in multiple myeloma

| PRJNA156981 | ENA

Homo sapiens

Project description:Clonal competition with alternating dominance in multiple myeloma [44kCGH]

| PRJNA157185 | ENA

Homo sapiens

Project description:Clonal competition with alternating dominance in multiple myeloma [244kCGH]

| PRJNA157183 | ENA

Homo sapiens

Project description:Clonal competition with alternating dominance in multiple myeloma [GEP]

| PRJNA157187 | ENA

Clonal competition with alternating dominance in multiple myeloma [44kCGH]

Project description:Copy number and Gene expression profiling multiple myeloma patients at multiple stages of their individual clinical course Identification of evolutionary paterns in multiple myeloma Copy number differences between individual CD138 purified tumor populations from multiple myeloma patients and control female using the Agilent 44B Human CGH microarray

2012-03-27 | E-GEOD-36823 | biostudies-arrayexpress

Clonal competition with alternating dominance in multiple myeloma [244kCGH]

2012-03-27 | E-GEOD-36822 | biostudies-arrayexpress

Clonal competition with alternating dominance in multiple myeloma [GEP]

Project description:Copy number and expression profiling of multiple myeloma patients at multiple stages of their individual clinical course Identification of evolutionary patterns in multiple myeloma Gene expression analysis of individual CD138 purified tumor populations using Affymertix U133Plus2.0 GeneChips

2012-03-27 | E-GEOD-36824 | biostudies-arrayexpress

MMRC aCGH reference collection

Project description:The MMRC reference collection is a dataset of gene expression profiling, array comparative genomic hybridization, and re-sequencing created as a resource for the Multiple Myeloma research community. CD138 purified bone marrow cells from patients with newly diagnosed and relapsed Multiple Myeloma.

2011-01-26 | E-GEOD-26849 | biostudies-arrayexpress

Receptor tyrosine kinase dependent phospho-signaling networks determine cellular growth and survival in acute lymphoblastic leukemia

Project description:Receptor tyrosine kinase (RTK)-dependent signaling has been implicated in the pathogenesis of acute lymphoblastic leukemia (ALL) of childhood. However, the RTK-dependent signaling state and its interpretation with regard to biological behavior are often elusive. To decipher signaling circuits that link RTK activity with biological output in vivo, we established patient-derived xenograft ALL (PDX-ALL) models with dependencies on fms-like tyrosine kinase 3 (FLT3) and platelet-derived growth factor receptor β (PDGFRB), which were interrogated by phosphoproteomics using iTRAQ mass spectrometry. Signaling circuits were determined by receptor type and cellular context with few generic features, among which we identified group I p21-activated kinases (PAKs) as potential therapeutic targets. Growth factor stimulation markedly increased catalytic activities of PAK1 and PAK2. RNA interference (RNAi)-mediated or pharmacological inhibition of PAKs using allosteric or adenosine triphosphate (ATP)-competitive compounds attenuated cell growth and increased apoptosis in vitro. Notably, PAK1- or PAK2-directed RNAi enhanced the antiproliferative effects of the type III RTK and protein kinase C inhibitor midostaurin. Treatment of FLT3- or PDGFRB-dependent ALLs with ATP-competitive PAK inhibitors markedly decreased catalytic activities of both PAK isoforms. In FLT3-driven ALL, this effect was augmented by coadministration of midostaurin resulting in synergistic effects on growth inhibition and apoptosis. Finally, combined treatment of FLT3 D835H PDX-ALL with the ATP-competitive group I PAK inhibitor FRAX486 and midostaurin in vivo significantly prolonged leukemia progression-free survival compared with midostaurin monotherapy or control. Our study establishes PAKs as potential downstream targets in RTK-dependent ALL of childhood, the inhibition of which might help prevent the selection or acquisition of resistance mutations toward tyrosine kinase inhibitors.

2019-11-22 | PRD000749 | Pride

Transcription profiling by array of human CD138 purified bone marrow plasma cells from relapsed multiple myeloma patients

Project description:Gene expression profiling of CD138 purified bone marrow plasma cells of relapsed multiple myeloma patients

2017-02-09 | E-MTAB-4715 | biostudies-arrayexpress